retired career service personnel is partly attributable to the double-digit growth in expenditures for prescription drugs.
At a time when the federal government is shaping the prescription drug benefi t that will be off ered to elderly Medicare recipients, the Department of Defense (DoD) asked researchers at the RAND Center for Military Health Care Policy to assist it in assessing factors contributing to the rising costs of prescription medications for military retirees and their families and proposing measures that might curb those costs without sacrifi cing patient safety or the quality of care.
Because a prescription fi lled at a retail pharmacy is substantially more costly to DoD than the same prescription dispensed from a military treatment facility (MTF) or mail-order pharmacy, the researchers fi rst assessed paticipants' choice of dispensing location. Th e researchers then examined the potential cost-savings of implementing a three-tier drug benefi t. Th eir fi ndings are as follows:
• Military retirees continue to fi ll more than half of their prescriptions at MTFs or through the military's TRICARE Mail Order Pharmacy (TMOP), but a growing number-currently 43 percent-are fi lling their prescriptions at retail pharmacies.
• Th e majority of pharmaceutical costs is incurred from drugs obtained at retail pharmacies, because the cost of those drugs to DoD is higher than the cost of the same drugs dispensed from an MTF or a mail-order pharmacy. Th us, DoD costs could decrease if retirees shifted from retail pharmacies to military facilities or the TMOP.
• Use of retail pharmacies is related to the distance to the nearest MTF and to the non-availability of certain highercost popular drugs at MTFs.
• Analysis of health insurance data from large private employers shows that implementing a three-tier drug benefi t in the military health system could slow the rate of increase in spending on pharmaceuticals.
• To achieve the signifi cant cost savings suggested in this study without adversely aff ecting the health status of benefi ciaries, DoD should carefully consider the drugs and drug classes that it places in the more-costly third tier.
Under the TRICARE Senior Pharmacy Program, Where Prescriptions Are Filled Affects Costs
In 2001, Congress mandated expanding pharmacy coverage for the 1.8 million elderly military retirees-those 65 and over-and their elderly dependents. Prior to that expansion of coverage, seniors could use their military prescription benefi t only at MTF pharmacies, where prescriptions were dispensed at no cost. Under the TRICARE Senior Pharmacy Program (TSRx), retired seniors could now use their TRI-CARE pharmacy benefi t to obtain prescriptions through any one of four sources: (1) MTF pharmacies, (2) retail pharmacies that are part of the TRICARE network, (3) the TMOP, and (4) non-network retail pharmacies. A modest copayment is applied to all prescriptions dispensed through network retail pharmacies and the TMOP-$3 for a generic drug and $9 for a brand-name drug (non-network retail pharmacies charge a higher copay)-whereas prescriptions are obtained at no cost from MTF pharmacies (see Table 1 ). While DoD's pharmaceutical costs were rising fairly steadily before the expansion of coverage, those costs suddenly accelerated in 2001 due in part to the change in the structure of the pharmacy benefi t (the expansion of coverage) and in part to a general trend seen in the civilian population as well. Costs to DoD for medications obtained from retail pharmacies are typically higher than the costs DoD is able to negotiate with pharmaceutical companies for medications dispensed through MTFs and the TMOP. Th us, the cost to DoD of allowing TRICARE participants to fi ll prescriptions at retail pharmacies is signifi cantly higher than if prescriptions were fi lled only through MTFs and the TMOP, particularly for high-price, widely prescribed drugs. If, for example, in 2001, seniors began fi lling a considerable proportion of their prescriptions at retail pharmacies, the switch in dispensing location could have been a factor in the increasing costs of drugs. Th us, as a fi rst step in identifying the causes of the rapidly rising costs and devising methods to cut those costs, RAND researchers were asked to assess where senior TRICARE benefi ciaries purchase their prescription drugs.
By examining TRICARE pharmacy claims data, the researchers found that the majority of TSRx prescriptions has been dispensed from MTFs (see the fi gure). However, they also noted a major decline in the use of MTFs for prescriptions-from 100 percent to 60 percent of prescriptions in the two years following the launch of the new programand a corresponding increase in the use of retail pharmacies.
Th e upside of the policy change for benefi ciaries included expanded access to-and availability of-pharmaceuticals. And TRICARE experienced an infl ux of new pharmacy benefi t users. Yet, for DoD, the new policy had a considerable downside: Although most TSRx prescriptions were still dispensed from MTFs or through mail order, the researchers found that drugs dispensed from retail pharmacies accounted for the highest proportion of total pharmaceutical costs for the TSRx program (see the fi gure). Th us, TSRx costs would decrease if drug dispensing could be shifted from retail pharmacies to those sources where federal pricing limits DoD's drug costs. For example, if all prescriptions written for TSRx participants for Zocor (a cholesterol-lowering drug) alone were fi lled at MTFs or through the TMOP, DoD would save 76 percent of the retail cost of that drugalmost $14 million yearly (see Table 2 ).
What Kinds of Factors Infl uence Where TSRx Participants Fill Their Prescriptions?
Clearly, if saving money were participants' only concern, most prescriptions would be fi lled at MTFs, which charge no copayment. Th us, researchers considered other factorsproximity of the nearest MTF to participants' residences and the availability of widely used medications at MTFs.
It is well recognized that proximity of a business that off ers a needed product or service increases the likelihood that consumers will use that business. Th e researchers used the residential zip codes of senior TRICARE participants to measure the distance participants must travel to the nearest MTF. When researchers compared the distance between military retirees and the nearest MTF with their pharmacy use, they found that retirees who reside within 20 miles of an MTF are more likely to participate in TSRx and to use an MTF to fi ll their prescriptions than retirees who live more than 20 miles from an MTF. As such, the farther a participant lives from an MTF, the more likely he or she is to use retail pharmacies or the TMOP instead of the MTF (see Table 3 ). And proximity to an MTF aff ects not only whether a retiree uses the MTF but the proportion of prescriptions he or she fi lls at the MTF. Most Americans live within fi ve miles of a retail pharmacy, while more than half of TSRx participants live more than 20 miles from an MTF. Th us, it is not surprising that a population of older individuals, who may limit the distances they drive for health or economic reasons, would seek the more accessible pharmacy.
Th e researchers also considered the availability of medications widely used by seniors. Th e products carried by each MTF pharmacy are determined by a formulary established by the DoD. Within each therapeutic class, the DoD Pharmacy & Th erapeutics Committee designates a particular brand or brands of drugs as being "preferred," based on several factors, including the negotiated cost of that brand to the DoD. When a generic drug is available, it is generally the preferred drug. MTFs do not dispense "non-preferred" drugs (i.e., name brands, which are usually more costly) unless a military physician documents medical necessity. Prescriptions for non-preferred drugs generally must be fi lled at a retail pharmacy. After examining the choice of dispensing locations by participants who had prescriptions for two of the most commonly prescribed types of drugs (cholesterollowering drugs and antacids), the researchers found that availability of a drug at an MTF was associated with greater use of the MTF, not only to obtain that drug but to also obtain other prescriptions. But if an MTF did not off er a certain drug, users who turned to a retail pharmacy to fi ll their prescriptions for the drug were more likely to also fi ll their other prescriptions at the retail pharmacy. Th e eff ects of proximity and the availability of nonpreferred drugs suggest that convenience strongly infl uences the decision to use retail pharmacies. However, to manage costs, DoD must identify ways to encourage more seniors to fi ll their prescriptions at MTFs or through the TMOP, or to at least discourage use of retail pharmacies. Options under consideration include (1) making MTF pharmacies more accessible by creating more of them or by providing delivery service from MTFs to participants' homes, (2) allowing benefi ciaries to obtain non-preferred drugs from the TMOP without proof of medical necessity (while at the same time no longer reimbursing benefi ciaries for non-formulary drugs obtained at retail pharmacies), and (3) increasing copays for non-preferred drugs. In a follow-up to this study, the researchers were asked to explore the likely consequences of the third alternative, which would add a third tier to the copay structure currently used by TRICARE.
Changing How Much TRICARE Benefi ciaries Pay for Prescription Drugs
In its eff ort to increase the effi ciency and integration of its pharmacy benefi ts program as well as to control the costs of prescription drugs, DoD is in the process of standardizing the drugs available at each MTF by establishing a Uniform Formulary. As part of this eff ort, DoD is considering moving from a two-tier to a three-tier copayment system. Under a two-tier system, lower-cost (i.e., preferred) drugs are off ered to participants at no cost or for a lower copayment than is charged for non-preferred brands in the same therapeutic class of drug. Th e proposed three-tier system would impose a $22 copay for non-preferred prescription medications for all TRICARE participants (see Table 1 ). Th e RAND researchers were asked to assist DoD in assessing the potential implications of this change-that is, how such a change might aff ect (1) DoD's costs and (2) benefi ciaries' out-of-pocket costs and use of drugs. To address this issue, the researchers examined how benefi ciaries with private drug coverage responded to similar changes in benefi ts, using data gathered by a private health benefi ts company.
Specifi cally, the researchers assessed how changes in plan expenditures, drug use, and participants' costs over one year's time compared between plans that switched from two to three tiers and those that remained the same. (Table 4 shows average copayments for each plan type.) Th ey also assessed whether the use and cost of some therapeutic classes of drugs were more aff ected by the changes than the use and cost of other classes of drugs and whether the demand for particular drugs was aff ected. Th e researchers found that from 1999 to 2000, the rate of increase in pharmacy spending was signifi cantly smaller in plans that switched from two to three tiers than in fi xed two-tier health plans (see Table 5 ). However, benefi ciaries' out-of-pocket spending grew considerably more rapidly for those enrolled in three-tier plans-both new and fi xedthan for those enrolled in fi xed two-tiered plans. Th is pattern was observed for most high-cost therapeutic classes of drugs, such as medications for asthma, high cholesterol, gastric acid disorders, and depression.
Th is study showed that civilian plans that implemented changes in their benefi t structure that were similar to the changes proposed for the military's Uniform Formulary achieved signifi cant savings in the year following the changes. However, some diff erences between the proposed Uniform Formulary and the changes in benefi t structures that were the subject of this study may limit the applicability of the fi ndings to DoD. For example, TRICARE's formulary restrictions and prior authorization requirements may diff er from those of the plans for which data were evaluated, and a number of factors such as discounts and rebates could not be taken into account. Further, the proposed Uniform Formulary would allow third-tier drugs to be obtained from the TMOP with no prior authorization and a lower copay than if the drugs were purchased from retail pharmacies. While this policy would work against trying to switch users to less costly drugs, it might, in the long run, encourage less use of the more costly retail pharmacies and greater use of the less costly TMOP.
Implications for DoD, TSRx, and Medicare
If the DoD elects to implement the three-tier Uniform Formulary, it will need to make a number of decisions. For example, to achieve savings without adverse health consequences, DoD should carefully consider the drugs and drug classes that it places in the non-preferred third tier. Criteria for selection include the availability of suitable substitutes, the level of spending on the class overall and on specifi c drugs in particular, and potential unintended consequences from switching medications. Th e most heavily scrutinized drugs should be those in the costliest therapeutic classes, which account for a disproportionate share of expenditures.
In addition, to achieve greater cost savings, DoD must assess the possible advantage of lowering the copay for thirdtier medications obtained from the TMOP, easing some of the prior authorization requirements at MTFs, and instituting other changes that would limit the incentive to use retail pharmacies.
Policymakers must also consider whether reduced pharmaceutical use or a switch to generic alternatives, which might result from higher patient copays and the change in benefi t structure, would have an adverse eff ect on health. Th e likelihood of seeing such eff ects on health is minimized if the third, and most costly, tier is reserved for drugs with close generic substitutes.
Th e Medicare Modernization Act (MMA) of 2003 has added a prescription drug benefi t to the Medicare Program. Under the new plan, individual participants may be responsible for $2,850 in expenses. Under MMA, the federal government has encouraged the private plans that administer Medicare benefi ts to devise ways to eliminate this potential gap in coverage. One proposal is to implement a three-tier copay structure. Th us, a fi nding of the RAND study-that copays matter-is of interest not only to DoD as it restructures the pharmacy benefi t for active duty military personnel and retirees but to the civilian sector as it seeks ways to control and redirect the costs of medications for the Medicare population. This PDF document was made available from www.rand.org as a public service of the RAND Corporation.
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